Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Seattle Genetics submits supplemental BLA for Adcetris in CTCL

June 21, 2017

Heidelberg Pharma and Takeda sign exclusive multitarget research agreement

June 21, 2017

Enrollment to begin in phase I/II trial of Ceplene for the treatment of CMML

June 21, 2017

Unum Therapeutics announces active IND for ACTR-707

June 21, 2017

Cell Medica acquires Catapult Therapy TCR

June 20, 2017

Tessa Therapeutics enters alliance with Parker Institute for Cancer Immunotherapy

June 20, 2017

EC approves biosimilar rituximab from Sandoz

June 20, 2017

Seattle Genetics halting phase III CASCADE study of vadastuximab talirine

June 20, 2017

Genmab reports data from cervical cancer cohort of phase I/II study of tisotumab vedotin

June 19, 2017

Immunocore and Adaptimmune describe novel SLC45A2-derived peptides

June 19, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...